Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
m Tag: visualeditor |
m Tag: visualeditor |
||
| Line 13: | Line 13: | ||
|Drilon et al. 2019 | |Drilon et al. 2019 | ||
| − | LIBRETTO-001 | + | LIBRETTO-001 |
| | | | ||
|Phase I/II | |Phase I/II | ||
| Line 23: | Line 23: | ||
'''Chemotherapy''' | '''Chemotherapy''' | ||
| − | *Selpercatinib 120 mg (<50 kg) and 160 mg (<u>></u>50 kg) orally twice daily | + | *Selpercatinib 120 mg (<50 kg) and 160 mg (<u>></u>50 kg) orally twice daily with or without food |
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| Line 34: | Line 34: | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Lung cancers]] | [[Category:Lung cancers]] | ||
| − | |||
Revision as of 03:30, 14 July 2020
Metastatic disease
Selpercatinib monotherpay
Regimen
| FDA-recommended dose |
|---|
| Study | Years of enrollment | Evidence |
|---|---|---|
| Drilon et al. 2019
LIBRETTO-001 |
Phase I/II |
Biomarker eligibility criteria
- Biomarker: RET fusion positive
Chemotherapy
- Selpercatinib 120 mg (<50 kg) and 160 mg (>50 kg) orally twice daily with or without food
Continued indefinitely
References
- Abstract. Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. link to abstract.